BNP Paribas’ European strength for Asian entrepreneurs and families


As Asia’s private wealth landscape continues to expand, families and entrepreneurs are seeking ever more sophisticated solutions to manage, protect and grow their assets. This dynamic environment is driving the evolution of family office strategies that move beyond conventional models to focus not only on wealth creation but also on long-term preservation and seamless succession.

Navigating Asia’s wealth hubs

BNP Paribas Wealth Management’s presence in Asia is built on dual hubs in Hong Kong and Singapore. This dual-platform approach enables the bank to offer clients flexibility and access to the region’s most important financial centres.

“Having strong bases in Hong Kong and Singapore allows us to address the unique opportunities and challenges within Greater China, Southeast Asia and beyond,” explains Arnaud Tellier, Asia Pacific CEO at BNP Paribas Wealth Management. “Each hub offers distinct strengths, but together they provide our clients with seamless access to the region’s most important financial centres.”

Arnaud Tellier, Asia Pacific CEO at BNP Paribas Wealth Management.
Arnaud Tellier, Asia Pacific CEO at BNP Paribas Wealth Management.

Hong Kong remains a key gateway, especially for the wealth being generated in Greater China. “The IPO boom in Hong Kong is a positive indicator for the region, and many entrepreneurs are choosing to list locally to access global investors. Despite domestic challenges, we continue to see substantial wealth creation flowing through Hong Kong,” Tellier notes.

  • Related Posts

    Singapore property clan puts rare Hong Kong estate up for US$38.4 million tender

    A Singapore-rooted property family has put a rare residential estate in Hong Kong’s Southern district up for tender at about HK$300 million (US$38.4 million), testing demand for trophy homes as…

    Continue reading
    China investors energise Hong Kong biotech stocks. Is foreign money missing out?

    Mainland Chinese investors can now buy shares in more than a dozen newly added Hong Kong-listed biotech and pharmaceutical companies after a reshuffle of the Stock Connect southbound trading list…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *